BPC-157 Dosage Guide 2026: Exact Oral, SubQ, and IM Protocols for Each Injury Type

This evidence-based peptide dosing guide shows precisely how clinicians use BPC-157 in 2026: milligram and microgram ranges by route, cycle lengths that appear effective in animals and the few human case reports, and the safety and legal caveats you need to know before starting.

Reviewed for general education · Updated August 2026 · 11 min read

The most common research-grade BPC-157 dose in 2026 is 2–4 mcg per kg of body weight once or twice daily for injections and 4–6 mcg / kg once or twice daily for oral capsules. Subcutaneous (under-skin) injections are preferred for tendon and ligament injuries, while oral BPC-157 is usually chosen for gut or systemic inflammation. Cycles typically last 4–8 weeks, after which clinicians reassess pain scores, range of motion, and basic labs before deciding whether to continue.

Most animal and limited human case data cluster around 200–400 mcg daily for a 175-pound (79 kg) adult when injected subcutaneously.
Oral BPC-157 has roughly 50 percent lower bioavailability than injections, so effective capsule doses start 1.5–2 times higher.
Peptide vials are usually reconstituted with 0.9 percent bacteriostatic saline at a concentration of 250 mcg per 1 mL for precise micro-dosing.
Six-week cycles appear to balance tissue healing timeframes with cost and potential receptor desensitization.
Clinicians track C-reactive protein, creatinine kinase, and a comprehensive metabolic panel before and after a cycle to gauge systemic effects.

Bottom line: Start at 2–4 mcg / kg per day injected or 4–6 mcg / kg per day orally for 4–6 weeks, then taper or repeat only after objective healing markers improve.

What BPC-157 Is and How It Works

BPC-157 is a pentadecapeptide composed of 15 amino acids derived from a protective protein found in gastric juice. It modulates the nitric-oxide pathway, up-regulates vascular endothelial growth factor (VEGF), and accelerates fibroblast migration, which together promote tissue healing. Animal studies show reduced gastric ulcer size, faster ligament regrowth, and improved angiogenesis after BPC-157 exposure. (pubmed.ncbi.nlm.nih.gov)

Human evidence remains preliminary: as of 2026, no randomized controlled trials in humans have been published, though several single-patient case reports suggest improvements in Crohn’s disease and tendonitis.

For a deep dive into the emerging evidence, see our tracker BPC-157 human studies.

Oral vs Injection: Which Route for Which Injury?

Injections deliver the peptide directly to systemic circulation, leading to higher peak concentrations than capsules that must survive digestive enzymes. Consequently, subcutaneous or intramuscular administration is favored for musculoskeletal injuries, while oral BPC-157 is often reserved for gastrointestinal disorders where local exposure may be beneficial.

Bioavailability difference: preclinical pharmacokinetic work suggests oral absorption of approximately 40–60 percent compared with parenteral delivery, though exact human data are lacking. (sciencedirect.com)

Injection types: SubQ (pinched belly fat) allows slow release near connective tissue, and IM (into the muscle) may reach deeper tendon junctions. Both appear similarly effective in rodent rotator-cuff models.

💡 Tip

Rotate injection sites every 1–2 days to minimize localized irritation and ensure even peptide dispersion.

Exact Dosages by Injury or Condition

The dose tables below compile the most frequently used research protocols and clinician anecdotal reports in 2026. Always adjust based on response and under medical supervision.

Condition	Route	Starting Dose	Typical Range	Notes
Tendon or ligament tear	SubQ near injury	250 mcg daily	2–4 mcg / kg once daily	Divide into AM + PM injections for severe tears
Chronic joint pain	IM into muscle belly	300 mcg daily	3–5 mcg / kg daily	Often combined with TB-500
IBD, gastric ulcer	Oral capsule	500 mcg daily	4–6 mcg / kg daily	Split dose morning and night with food
Systemic inflammation	SubQ abdomen	200 mcg daily	2–3 mcg / kg daily	Monitor CRP monthly

Why micrograms not milligrams? Preclinical work shows a plateau in healing response above roughly 10 mcg / kg, so higher doses rarely improve outcomes and only raise cost.

Choosing a 4-, 6-, or 8-Week Cycle

Soft-tissue remodeling follows a predictable timeline, so the length of a BPC-157 cycle should match the biology of the target tissue.

Four-week cycles: minor sprains or early gut irritation often resolve within a month, making a short cycle cost-effective.

Six-week cycles: standard for moderate grade II ligament tears where collagen cross-linking peaks around week 6.

Eight-week cycles: selected for partial rotator-cuff or Achilles injuries that show slower vascularization.

Cycle Length	Tissue Healing Stage Targeted	Re-evaluation Point
4 weeks	Inflammatory + early proliferative	Week 4 pain score & ultrasound
6 weeks	Collagen proliferation	Week 6 MRI or functional test
8 weeks	Remodeling & mechanotransduction	Week 8 load-bearing strength

How to Mix and Store BPC-157 Safely

BPC-157 arrives lyophilized (freeze-dried) in 5-mg or 10-mg vials.

Step-by-step mixing:

1. Withdraw 4 mL of bacteriostatic water with a 29 G insulin syringe.

2. Inject slowly into the vial so the water runs down the glass side (avoids foaming).

3. Swirl gently until the powder dissolves completely.

This yields a 2.5 mg / mL solution, meaning each 0.1 mL equals 250 mcg, which matches the dose table for a typical 80 kg adult.

Storage: keep reconstituted vials refrigerated at 36–46 °F for up to 30 days. Discard if the solution turns cloudy.

⚠️ Off-label status

Because BPC-157 is not approved by the FDA, pharmacies cannot legally compound it for human use. Purchasing research peptides for self-injection carries quality and sterility risks. (fda.gov)

Lab Markers Clinicians Monitor

Although severe adverse events have not been reported in preclinical toxicity work, prudent prescribers still monitor baseline and follow-up labs to flag unexpected organ stress.

Test	Why It Matters	When Checked
Comprehensive metabolic panel	Liver enzymes and kidney function	Baseline and week 6
C-reactive protein (CRP)	Confirms reduction in systemic inflammation	Baseline and cycle end
Creatine kinase (CK)	Screens for muscle breakdown	Week 3 and week 6
Complete blood count	Detects unexpected cytopenias	Baseline and week 6
Fasting glucose	Rule out peptide-induced insulin changes	Baseline

Is a self-directed BPC-157 cycle reasonable for you?

Check the column that fits your situation:

✅ Probably safe to proceed

Minor grade I or II soft-tissue injury diagnosed by a clinician
No history of cancer, clotting disorder, or uncontrolled diabetes
Able to obtain sterile supplies and follow injection technique precisely
Will complete baseline and follow-up labs at weeks 0 and 6

🏥 See a doctor first

Active or recent malignancy of any type
Severe organ disease (kidney, liver, or heart failure)
History of stroke, pulmonary embolism, or DVT
Pregnant, breastfeeding, or planning conception
Current use of anticoagulants, corticosteroids, or immunosuppressants
Unsure of sterile injection technique or sourcing peptide quality

Risks, Side Effects, and Current Legal Status

Most reported side effects are mild and include localized redness, transient dizziness, or nausea. No signal for organ toxicity appeared in a 28-day canine study at 2 mg / kg. (sciencedirect.com)

Cancer concerns: animal work has shown angiogenesis stimulation, which theoretically could feed tumors, though no direct carcinogenic effect has been demonstrated. For details, read BPC-157 cancer risk.

FDA stance: the peptide is not on the FDA’s 503A or 503B bulks-list and the agency lists BPC-157 as presenting significant safety risks when used in compounded drugs. (fda.gov)

Multiple warning letters in 2024 cited peptide vendors for selling unapproved BPC-157 with disease claims. (fda.gov)

🚨 When to Contact Your Healthcare Provider

Contact your doctor immediately if you experience any of the following:

Swelling or warmth in a calf - could signal a blood clot.
Sudden severe headache or vision changes - may indicate an intracranial event.
Chest pain or shortness of breath - rule out pulmonary embolism.
Rapid weight gain or leg edema - potential kidney or heart involvement.
Persistent abdominal pain or dark stools - possible GI bleeding.
Injection-site abscess - requires prompt drainage and antibiotics.
New unexplained lumps - evaluate for tumor growth.
Thoughts of self-harm - call 988 in the United States for 24 / 7 crisis help.

Scientific References

Frequently Asked Questions

Can I combine BPC-157 with TB-500 for faster healing?

Yes, many clinicians stack the two peptides because TB-500 mobilizes actin for cell migration while BPC-157 improves micro-vascularity, though no human trials confirm synergy. Dose each peptide on alternating days to reduce injection volume.

Is oral BPC-157 destroyed by stomach acid?

Enteric-coated capsules can protect the peptide until it reaches the small intestine, but bioavailability still appears roughly half that of injections, which is why oral doses are higher.

Do I need to taper off BPC-157?

No taper is required because the peptide does not suppress an endocrine axis. Many protocols simply stop at the end of the cycle and reassess symptoms two weeks later.

How soon should I feel pain relief?

Some users report reduced discomfort within 7 days, but measurable structural healing of tendons usually takes at least 4 weeks, confirmed via imaging or functional testing.

Can BPC-157 make scar tissue worse?

Current animal data suggest the peptide organizes collagen fibers in a more parallel and flexible pattern, which may actually reduce adhesions rather than worsen them.

Is BPC-157 allowed in professional sports?

No. The World Anti-Doping Agency (WADA) lists BPC-157 under Section S0 as a non-approved substance, making it prohibited in-competition and out.

Does insurance cover BPC-157?

Because the peptide is not FDA-approved, no U.S. insurance plans reimburse its cost. Expect to pay out of pocket for research-grade supplies and lab monitoring.